Clinical trials: Acute Respiratory Viral Infections
Covid19, COVID-19 Pneumonia
Clinical Impact of COVID-19 by P.1 SARS-CoV-2 Lineage
Since the first report of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) P.1 in Manaus, Brazil, a rapid spread of this lineage across the country has been observed.
- Conditions
- Covid19, COVID-19 Pneumonia, SARS-CoV-2 Infection
- Trial name
- NCT04928469
- Testing
- No intervention performed
- Where
- Brazil
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Long Covid19, Autonomic Dysfunction
Autonomic Nervous System Affection Due to Post Covid Syndrome
Post-Covid syndrome is defined as symptoms that develop in addition to respiratory symptoms in individuals who have had Covid-19 infection for more than 12 weeks.
- Trial name
- NCT05502094
- Testing
- Heart Rate Variability Measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bahçeşehir University
Severe Acute Respiratory Syndrome
Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)
This study will evaluate and treat people with SARS, a new type of pneumonia (lung infection) originating in China. SARS is caused by a new virus that is easily transmitted from person to person.
- Trial name
- NCT00073086
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID, Covid-19
Trial of Combination Therapy to Treat COVID-19 Infection
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
- Conditions
- COVID, Covid-19, Corona Virus Infection, Coronavirus Infection
- Trial name
- NCT04482686
- Testing
- Ivermectin, Doxycycline Hcl, Zinc
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- ProgenaBiome
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.
- Trial name
- NCT05706454
- Testing
- Ramatroban
- Where
- 7 sites in India
- Volunteers
- 324 people
- Sponsor
- KARE Biosciences
Long-COVID, Post COVID-19 Condition
Sulfureous Water Therapy in Viral Respiratory Diseases
The goal of this double-blind, interventional, randomized case-control, pilot trial is to evaluate the effects of active sulfurous (STW) versus placebo (SDW) inhalations on blood test parameters, serum inflammatory cytokines…
- Conditions
- Long-COVID, Post COVID-19 Condition, Chronic COVID-19 Syndrome, Post Acute Sequelae of COVID-19
- Trial name
- STWandRVD (NCT06294756)
- Testing
- Inhalation of Sulfurous Thermal Water, Inhalation of Sterile Distilled non-pyrogenic Water
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Roma La Sapienza
Long Covid
The Effect of Acupuncture Treatment on Cognitive Functions and Brain Networks for Long COVID
Background of study: Long COVID(LC) is a prevalent sequalae of SARS-CoV-2 infection and can affect multiple organ systems. Cognitive dysfunction is one of the most common symptoms in LC with 22% prevalence.
- Trial name
- NCT07355751
- Testing
- Acupuncture
- Where
- 2 sites in China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Tingting Luo
ARDS, COVID19
Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS
The 2020 pandemic of the coronavirus (SARS-CoV2) has lead to an increase in ARDS cases requiring invasive mechanical ventilation in the ICU (Intensive Care Unit).
- Trial name
- APRV-COVID19 (NCT04386369)
- Testing
- Airway pressure release ventilation
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Central Hospital, Nancy, France
Covid19
A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection
This study aims to find out the efficacy of Xlear nasal spray as an adjunct medication against COVID-19. This encompasses reduction in the number of days to negativization via nasal swab PCR from the average 14 days and early…
- Trial name
- NCT04858620
- Testing
- Xlear Nasal Spray
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Larkin Community Hospital
Covid19, SARS-CoV Infection
Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil)
This is a registry-based cohort study of all adult patients (≥18 years) with confirmed or suspected SARS-CoV-2 infection. The main goal is to describe mortality incidence, demographic characteristics, coexisting conditions…
- Trial name
- SARS-Brazil (NCT04479488)
- Testing
- Hospital admission, Non-hospitalization procedures
- Where
- 14 sites in Brazil
- Volunteers
- 1,587 people
- Sponsor
- Hospital Israelita Albert Einstein
Covid19, Thrombotic Microangiopathies
Ravulizumab and COVID-19
Ultomiris (Ravulizumab), is a monoclonal antibody that specifically targets terminal complement products and is proposed for the treatment of COVID-19 induced microvasculature injury and endothelial damage leading to thrombotic…
- Conditions
- Covid19, Thrombotic Microangiopathies, Acute Kidney Injury
- Trial name
- NCT04570397
- Testing
- Ravulizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Brigham and Women's Hospital
Covid19, Severe Acute Respiratory Syndrome
Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19
Pilot clinical trial, with a marketed drug -natural component of human plasma-, not approved for this indication, single-center, exploratory, open, randomized, controlled, to study the efficacy and safety of human Antithrombin in…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, Distress Respiratory Syndrome
- Trial name
- NCT04745442
- Testing
- Antithrombin + best available treatment, Best available treatment
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia
Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2
In December 2019, the Municipal Health Committee of Wuhan, China, identified an outbreak of viral pneumonia of unknown cause. This new coronavirus was called SARS-CoV-2 and the disease caused by that virus, COVID-19.
- Trial name
- CloroCOVID19 (NCT04323527)
- Testing
- Chloroquine diphosphate
- Where
- Brazil
- Volunteers
- 278 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19 Related Health and Infection Control Practices Among Dentists
As dentists begin reopening their practices during a global pandemic, the risk of COVID-19 infection that dentists face in providing dental care remains unknown.
- Trial name
- NCT04423770
- Testing
- No intervention
- Where
- United States
- Volunteers
- 2,196 people, healthy volunteers welcome
- Sponsor
- American Dental Association
Reproductive Disorder, Neurodegeneration
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome.
- Conditions
- Reproductive Disorder, Neurodegeneration, SARS-CoV 2, Long COVID
- Trial name
- NCT07224490
- Testing
- Kisspeptin 112-121
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stephanie B. Seminara, MD
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Severe Influenza, Intensive Care (ICU)
Early Corticosteroids in Severe Influenza Pneumonia
This is a Phase III, multicentre, randomized, controlled, double-blind, superiority trial aiming to evaluate the efficacy of dexamethasone versus placebo in patients admitted to intensive care or intermediate care with influenza…
- Conditions
- Severe Influenza, Intensive Care (ICU), Reanimation, Infectious Diseases
- Trial name
- ECSIP (NCT07786662)
- Testing
- Dexametasone
- Where
- 48 sites in France
- Volunteers
- 544 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Sars-CoV-2 Infection, Long Covid19
Long Term Outcomes in COVID-19 Patients Recruited in the CORIST Project
Months after seemingly recovering from COVID-19, many patients continue to suffer from major long-term effects. Interestingly, the existence of direct link between the severity of the disease in its acute phase and the severity…
- Trial name
- CORIST-2 (NCT04907890)
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Acute Respiratory Distress Syndrome, COVID-19
Polyvalent Immunoglobulin in COVID-19 Related ARds
As of 30/03/2020, 715600 people have been infected with COVID-19 worldwide and 35500 people died, essentially due to respiratory distress syndrome (ARDS) complicated in 25% of the with acute renal failure.
- Trial name
- ICAR (NCT04350580)
- Testing
- Human immunoglobulin
- Where
- 42 sites in France
- Volunteers
- 146 people
- Sponsor
- Centre Hospitalier St Anne
Respiratory Infections, Acute, Respiratory Syncytial Virus
RSV Challenge in Healthy Adults
The purpose of this study is to measure the immune response (how the body fights infection) to an experimental preparation of live Respiratory Syncytial Virus (RSV).
- Trial name
- NCT00100373
- Testing
- RSV challenge material
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)